FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:208-209 January 20, 1994 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In most patients with cirrhosis of the liver, esophagogastric varices, a potentially life-threatening complication of portal hypertension, eventually develop. Twenty-five to 35 percent of these patients bleed from varices, usually within the first year after this complication is diagnosed. The rate of recurrent variceal bleeding approaches 70 percent, with most episodes occurring within one year after the initial episode. For each episode of variceal hemorrhage, the mortality is approximately 50 percent.

Over the past two decades, many new therapies have been introduced to control acute variceal hemorrhage and to prevent recurrent hemorrhage. These have included endoscopic techniques such as sclerotherapy . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.